6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
Titel:
6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
Auteur:
Arnold, D. Fernandez, E. Elez Van Cutsem, E. Ahmad, A.R. Lopez, C. Keranen, S. Rosello Velez, H. Eng, C. Pietrantonio, F. Garcia, V. Moreno Ducreux, M.P. Malik, R. Abdul Chowdhury, S. Lyu, X. Bhattacharya, R. Yilmaz, E. Daksh, M. Mahadevia, P. Baig, M. Heinemann, V.